Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Debt-to-Equity is 0.15 as of Mar. 2026, which is 12% below its 10-year median of 0.17. The stock has 1 warning sign investors should review. Among 183 Medical Diagnostics & Research companies, Invitro International ranks better than 65.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Invitro International's Debt-to-Equity or its related term are showing as below:
IVRO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.15 Med: 0.17 Max: 0.22
Current: 0.15
During the past 9 years, the highest Debt-to-Equity Ratio of Invitro International was 0.22. The lowest was 0.15. And the median was 0.17.
IVRO's Debt-to-Equity is ranked better than 65.57% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.32
vs IVRO: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Invitro International Debt-to-Equity Related Terms
Invitro International Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Invitro International's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVRO vs IDTA, PRPH, NSTM: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Invitro International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Invitro International's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Debt-to-Equity of 0.15 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Invitro International and its competitors. This is 12% below median its historical median of 0.17. Over the past decade, Invitro International's Debt-to-Equity has ranged from 0.15 to 0.22. According to the industry distribution chart, Invitro International ranks #63 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 34.4%.
Is Invitro International's Debt-to-Equity too high?
Invitro International's current Debt-to-Equity of 0.15 is 12% below median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.22. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.32. Invitro International's value of 0.15 is 53.1% below this industry median. Based on the distribution chart, Invitro International ranks #63 out of 183 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Invitro International's Debt-to-Equity compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #63 out of 183 companies for Debt-to-Equity. This puts Invitro International in the upper half of its industry. The industry median Debt-to-Equity is 0.32. Invitro International's value of 0.15 is 53.1% below this benchmark. Historically, Invitro International's own Debt-to-Equity has ranged from 0.15 to 0.22 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.32, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.32, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Debt-to-Equity of 0.15 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Debt-to-Equity is 0.15, which is 12% below median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Debt-to-Equity is 0.15, which is 12% below median its 10-year median of 0.17 and 53.1% below the Medical Diagnostics & Research industry median of 0.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Invitro International (IVRO), the current Debt-to-Equity is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
